MatsukiyoCocokara & (3088) Fundamentals 2026 — P/E 17.6x, Revenue Analysis | SniperIQ
MatsukiyoCocokara & (3088) is a JP-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥969.7B, trading at ¥2465.50 on the JPX. This SniperIQ fundamentals page covers MatsukiyoCocokara &'s valuation (P/E 17.6x, P/B 1.8x), profitability (net margin 5.0%), revenue (¥1.12T in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MatsukiyoCocokara &'s market cap?
MatsukiyoCocokara & (3088) has a market capitalization of approximately ¥969.7B, trading at ¥2465.50 on the JPX. Market cap moves with the live share price.
What is MatsukiyoCocokara &'s P/E ratio?
MatsukiyoCocokara &'s trailing twelve-month P/E ratio is 17.6x, with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MatsukiyoCocokara &?
MatsukiyoCocokara & runs a net profit margin of 5.0%, a gross margin of 34.2%, and an operating margin of 7.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MatsukiyoCocokara & generate?
MatsukiyoCocokara & reported revenue of ¥1.12T for fiscal year 2026, with net income of ¥55.8B and earnings per share (EPS) of 139.93. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MatsukiyoCocokara & pay a dividend?
MatsukiyoCocokara & offers a trailing dividend yield of about 2.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is MatsukiyoCocokara & financially healthy?
MatsukiyoCocokara & carries a debt-to-equity ratio of 0.01x and a current ratio of 2.21x, with a market beta of -0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MatsukiyoCocokara & a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MatsukiyoCocokara & (3088) the key facts are: market cap ¥969.7B, P/E 17.6x, revenue ¥1.12T, 52-week range 2171.5-3393. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MatsukiyoCocokara &'s full fundamentals live
Get MatsukiyoCocokara &'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.